AGBL2 and synovitis: Similar results were observed in the subgroup of high-level CCP2+ individuals at the 1 and 2 year follow-up; respectively, 19.4% and 32.7% of high-level CCP2+/anti-CCP3+, but only 2.6% and 10.3% of high-level CCP2+ individuals with negative anti-CCP3 antibodies developed subclinical synovitis on longitudinal scans (P = 0.01 and P < 0.01, respectively) (Fig. 2b).